Abstract
Guillain–Barre syndrome (GBS) is an acute-onset immune-mediated polyneuropathy characterized by ascending symmetrical muscle weakness, diminished reflexes, and sensory symptoms. While GBS typically follows a monophasic course, some patients experience treatment-related fluctuations or recurrences, posing diagnostic challenges in distinguishing GBS from acute-onset chronic inflammatory polyneuropathy (A-CIDP). A-CIDP, may present acutely, simulating GBS, with a nadir in less than 8 weeks, subsequently evolving into a chronic or relapsing course. The distinction between recurrent GBS and A-CIDP is crucial, as A-CIDP necessitates long-term immunosuppression. A PubMed search was conducted using the search terms ‘recurrent Guillain Barre syndrome’ and ‘acute onset CIDP’ focusing on studies in the English language, published between January 1, 2004 and April 30, 2023. Overlapping clinical features, particularly in the early stages, complicate differentiation between recurrent GBS and CIDP. Electrophysiological studies, ultrasonography, and immunological markers have been explored for discrimination; however, definitive criteria for differentiation remain elusive. Recent follow-up studies have further blurred the boundaries between recurrent GBS and A-CIDP, suggesting the persistence of underlying immune processes even in GBS patients without clinical deterioration. This emphasizes the necessity of reevaluating diagnostic criteria and treatment strategies. In conclusion, distinguishing recurrent GBS from A-CIDP remains an ongoing challenge. Existing evidence questions the categorization of recurrent GBS as a distinct entity, challenging its very existence. Continued research is necessary to refine diagnostic criteria and deepen our understanding of these conditions, ultimately advancing patient care. This review delves into the intricacies of recurrent GBS and A-CIDP differentiation and highlights the need for a reevaluation of the recurrent GBS concept.
Similar content being viewed by others
References
Ruts L, van Koningsveld R, van Doorn PA (2005) Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology 65(1):138–140. https://doi.org/10.1212/01.wnl.0000167549.09664.b8
Yuki N, Hartung HP (2012) Guillain-Barre syndrome. N Engl J Med 366(24):2294–2304. https://doi.org/10.1056/NEJMra1114525
Shahrizaila N, Lehmann HC, Kuwabara S (2021) Guillain-Barre syndrome. Lancet 397(10280):1214–1228. https://doi.org/10.1016/S0140-6736(21)00517-1
McGrogan A, Madle GC, Seaman HE, de Vries CS (2009) The epidemiology of Guillain-Barre syndrome worldwide a systematic literature review. Neuroepidemiology 32(2):150–163. https://doi.org/10.1159/000184748
Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 36(2):123–133. https://doi.org/10.1159/000324710
Doets AY, Verboon C, van den Berg B et al (2018) Regional variation of Guillain-Barre syndrome. Brain 141(10):2866–2877. https://doi.org/10.1093/brain/awy232
Bae JS, Yuki N, Kuwabara S et al (2014) Guillain-Barre syndrome in Asia. J Neurol Neurosurg Psychiatry 85(8):907–913. https://doi.org/10.1136/jnnp-2013-306212
Leonhard SE, van der Eijk AA, Andersen H et al (2022) An international perspective on preceding infections in Guillain-Barre syndrome: the IGOS-1000 cohort. Neurology 99(12):e1299–e1313. https://doi.org/10.1212/WNL.0000000000200885
McDonnell EP, Altomare NJ, Parekh YH et al (2020) COVID-19 as a trigger of recurrent Guillain-Barre syndrome. Pathogens. https://doi.org/10.3390/pathogens9110965
de Castro G, Bastos PG, Martinez R, de Castro Figueiredo JF (2006) Episodes of Guillain-Barré syndrome associated with the acute phase of HIV-1 infection and with recurrence of viremia. Arq Neuropsiquiatr 64(3a):606–8. https://doi.org/10.1590/s0004-282x2006000400016
Fotiadou A, Tsiptsios D, Karatzetzou S, Kitmeridou S, Iliopoulos I (2022) Acute-onset chronic inflammatory demyelinating polyneuropathy complicating SARS-CoV-2 infection and Ad26.COV2.S vaccination: report of two cases. Egypt J Neurol Psychiatr Neurosurg 58(1):116. https://doi.org/10.1186/s41983-022-00515-4
Bellucci M, Germano F, Grisanti S et al (2022) Case report: post-COVID-19 vaccine recurrence of Guillain-Barre syndrome following an antecedent parainfectious COVID-19-related GBS. Front Immunol 13:894872. https://doi.org/10.3389/fimmu.2022.894872
Suri V, Pandey S, Singh J, Jena A (2021) Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination. BMJ Case Rep. https://doi.org/10.1136/bcr-2021-245816
Leonhard SE, Munts AG, van der Eijk AA, Jacobs BC (2018) Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. J Neurol Neurosurg Psychiatry 89(10):1118–1119. https://doi.org/10.1136/jnnp-2017-317346
Yang B, Lian Y, Liu Y, Wu BY, Duan RS (2016) A retrospective analysis of possible triggers of Guillain-Barre syndrome. J Neuroimmunol 293:17–21. https://doi.org/10.1016/j.jneuroim.2016.02.003
Huang C, Zhang Y, Deng S, Ren Y, Lu W (2020) Trauma-related Guillain-Barre syndrome: systematic review of an emerging concept. Front Neurol 11:588290. https://doi.org/10.3389/fneur.2020.588290
Leonhard SE, Mandarakas MR, Gondim FAA et al (2019) Diagnosis and management of Guillain-Barre syndrome in ten steps. Nat Rev Neurol 15(11):671–683. https://doi.org/10.1038/s41582-019-0250-9
Verboon C, Doets AY, Galassi G et al (2019) Current treatment practice of Guillain-Barre syndrome. Neurology 93(1):e59–e76. https://doi.org/10.1212/WNL.0000000000007719
Alessandro L, Castiglione JI, Brand P, Bruno V, Barroso F (2022) Treatment-related fluctuations in Guillain-Barre syndrome: clinical features and predictors of recurrence. Arq Neuropsiquiatr 80(5):516–522. https://doi.org/10.1590/0004-282X-ANP-2021-0226
Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBSSG (2010) Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 74(21):1680–6. https://doi.org/10.1212/WNL.0b013e3181e07d14
Das A, Kalita J, Misra UK (2004) Recurrent Guillain Barre’ syndrome. Electromyogr Clin Neurophysiol 44(2):95–102
Wang S, Luo Z, Peng T (2022) Serum thyroid-stimulating hormone is an independent risk factor of recurrent Guillain-Barre syndrome. Muscle Nerve 65(6):688–692. https://doi.org/10.1002/mus.27539
Dalakas MC, Medscape, (2011) Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 7(9):07–17. https://doi.org/10.1038/nrneurol.2011.121
Van den Bergh PY, Hadden RD, Bouche P et al (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 17(3):356–363. https://doi.org/10.1111/j.1468-1331.2009.02930.x
Alessandro L, Pastor Rueda JM, Wilken M et al (2018) Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. J Peripher Nerv Syst. 23(3):154–8. https://doi.org/10.1111/jns.12266
Anadani M, Katirji B (2015) Acute-onset chronic inflammatory demyelinating polyneuropathy: an electrodiagnostic study. Muscle Nerve 52(5):900–905. https://doi.org/10.1002/mus.24667
Basta I, Bozovic I, Berisavac I et al (2019) Recurrent Guillain-Barre syndrome—case Series. Neurol India 67(6):1536–1538. https://doi.org/10.4103/0028-3886.273649
Ishii J, Yuki N, Kawamoto M, Yoshimura H, Kusunoki S, Kohara N (2016) Recurrent Guillain-Barre syndrome, Miller Fisher syndrome and Bickerstaff brainstem encephalitis. J Neurol Sci 364:59–64. https://doi.org/10.1016/j.jns.2016.03.008
Kuitwaard K, van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA (2009) Recurrent Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 80(1):56–59. https://doi.org/10.1136/jnnp.2008.156463
Chohan S, Chohan A (2022) Recurrence of a rare subtype of Guillain-Barre syndrome following a second dose of the shingles vaccine. Cureus 14(10):e30717. https://doi.org/10.7759/cureus.30717
Yelam A, Nagarajan E, Govindarajan R, Bollu PC (2018) A Rare case of recurrent Guillain-Barre syndrome without albuminocytological dissociation. BMJ Case Rep. https://doi.org/10.1136/bcr-2018-226572
Jo YS, Choi JY, Chung H, Kim Y, Na SJ (2018) Recurrent Guillain-Barre syndrome following urinary tract infection by Escherichia coli. J Korean Med Sci 33(4):e29. https://doi.org/10.3346/jkms.2018.33.e29
Mossberg N, Nordin M, Movitz C et al (2012) The recurrent Guillain-Barre syndrome: a long-term population-based study. Acta Neurol Scand 126(3):154–161. https://doi.org/10.1111/j.1600-0404.2012.01667.x
Ling L, Bagshaw SM, Villeneuve PM (2021) Guillain-Barre syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barre syndrome. CMAJ 193(46):E1766–E1769. https://doi.org/10.1503/cmaj.210947
Imam K, Liu A (2020) A case of recurrent Guillain-Barre syndrome observed by the same clinician 12 years apart. Clin Case Rep 8(8):1376–1378. https://doi.org/10.1002/ccr3.2903
Togawa J, Nakaoku Y, Hagiwara M et al (2015) Similarities of serum anti-ganglioside antibodies in first and third episodes of recurrent Guillain-Barre syndrome: case report. J Neurol 262(5):1360–1362. https://doi.org/10.1007/s00415-015-7714-7
Dy M, Leshner RL, Crawford JR (2013) An unusual case of recurrent guillain-barre syndrome of a different subtype five years after initial diagnosis. Case Rep Neurol Med 2013:356157. https://doi.org/10.1155/2013/356157
Yalinay Dikmen P, Emre Oge A (2012) Recurrent GBS with GD1a anti-ganglioside antibodies. J Peripher Nerv Syst 17(1):135–7. https://doi.org/10.1111/j.1529-8027.2012.00384.x
Notturno F, Kokubun N, Sekiguki Y et al (2016) Demyelinating Guillain-Barré syndrome recurs more frequently than axonal subtypes. J Neurol Sci 365:132–136. https://doi.org/10.1016/j.jns.2016.02.053
Takemoto K, Kawahara M, Atagi K (2023) Recurrent Guillain-Barre syndrome associated with the second episode of campylobacter jejuni infection: a case report. Intern Med. https://doi.org/10.2169/internalmedicine.1094-22
Griffin G, Cunningham B, Beary JM, Spolter Y, Gandee R, Newey CR (2021) Lighting strikes twice: recurrent Guillain-Barre Syndrome (GBS) after influenza vaccination. Case Rep Neurol Med 2021:6690643. https://doi.org/10.1155/2021/6690643
Takahashi H, Kimura T, Yuki N, Yoshioka A (2018) An adult case of recurrent Guillain-Barre syndrome with anti-galactocerebroside antibodies. Intern Med 57(3):409–412. https://doi.org/10.2169/internalmedicine.8941-17
Pyun SY, Jeong JH, Bae JS (2015) Recurrent Guillain-Barre syndrome presenting stereotypic manifestations, positive antiganglioside antibodies, and rapid recovery. Clin Neurol Neurosurg 139:230–233. https://doi.org/10.1016/j.clineuro.2015.10.022
Heckmann JG, Dütsch M (2012) Recurrent Miller Fisher syndrome: clinical and laboratory features. Eur J Neurol 19(7):944–954. https://doi.org/10.1111/j.1468-1331.2011.03584.x
Hwang J, Kwon YJ, Kim JK, Kim NJ, Baek SH (2019) Recurrent Guillain-Barre syndrome with anti-GT1a and anti-GQ1b ganglioside antibodies. J Clin Neurol 15(3):404–406. https://doi.org/10.3988/jcn.2019.15.3.404
Martic V, Lepic T (2007) Recurrence of childhood Guillain-Barre syndrome after a long asymptomatic interval: a case report. J Clin Neuromuscul Dis 9(1):256–261. https://doi.org/10.1097/CND.0b013e3181563d90
Bekircan-Kurt C.E., F. Yildiz, C. Temucin, A. Tuncer Kurne, E. Tan, S. Erdem Ozdamar. 2017 Recurrent peripheral and central demyelination in a seronegative patient. in Peripheral Nerve Society Annual Meeting. Barcelona, Spain.
Doneddu PE, Bianchi E, Cocito D et al (2020) Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits data from the Italian CIDP database. Eur J Neurol 27(1):136–43. https://doi.org/10.1111/ene.14044
Abraham H, Kuzhively J, Rizvi SW (2017) Chronic inflammatory demyelinating polyneuropathy (CIDP): an uncommon manifestation of systemic lupus erythematosus (SLE). Am J Case Rep 18:980–983. https://doi.org/10.12659/ajcr.903541
Vialatte de Pemille C, Noel N, Adam C et al (2023) Red flags for chronic inflammatory demyelinating polyradiculoneuropathy associated with sarcoidosis or connective tissue diseases. J Clin Med. https://doi.org/10.3390/jcm12093281
Julio PR, Cortes MMM, Costallat LTL, Gaino JZ, Franca MC Jr, Appenzeller S (2021) Chronic inflammatory demyelinating polyradiculoneuropathy associated with systemic lupus erythematosus. Semin Arthritis Rheum 51(1):158–165. https://doi.org/10.1016/j.semarthrit.2020.09.018
Toledano P, Orueta R, Rodriguez-Pinto I, Valls-Sole J, Cervera R, Espinosa G (2017) Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmun Rev 16(7):750–755. https://doi.org/10.1016/j.autrev.2017.05.011
Kuitwaard K, van der Pol WL, Ruts L, van Doorn PA (2009) Individual patients who experienced both Guillain-Barre syndrome and CIDP. J Peripher Nerv Syst 14(1):66–68. https://doi.org/10.1111/j.1529-8027.2009.00208.x
Rajabally YA, Peric S, Bozovic I et al (2021) Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: a European collaborative study. Muscle Nerve 64(6):657–661. https://doi.org/10.1002/mus.27374
Mansour M, Ouerdiene A, Bedoui I, Kacem A, Zaouali J, Mrissa R (2020) Acute-onset chronic inflammatory demyelinating polyneuropathy with cranial nerves and respiratory tract involvement: a case report. Clin Case Rep 8(11):2199–2203. https://doi.org/10.1002/ccr3.3087
Dennis E, Hartman E, Cortes-Penfield N, Piccione E, Thaisetthawatkul P (2023) Acute and Chronic demyelinating neuropathies after COVID-19 vaccination: a report of 4 cases. J Clin Neuromuscul Dis 24(3):147–156. https://doi.org/10.1097/CND.0000000000000418
Klehmet J, Marschenz S, Ruprecht K et al (2018) Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP). Clin Chem Lab Med 56(6):919–926. https://doi.org/10.1515/cclm-2017-0792
Patnaik AP, Mininni J, Porter NC, Morris NA (2021) A severe course of relapsing-remitting acute-onset chronic inflammatory demyelinating polyneuropathy in a young man. Case Rep Neurol 13(1):73–77. https://doi.org/10.1159/000511956
Kim W, An JY (2021) Vaccination-associated acute-onset chronic inflammatory demyelinating polyneuropathy followed by acute disseminated encephalomyelitis in a postpartum woman. Acta Neurol Belg 121(3):771–774. https://doi.org/10.1007/s13760-020-01468-2
Bert-Marcaz C, Briantais A, Faucher B et al (2022) Expanding the spectrum of VEXAS syndrome: association with acute-onset CIDP. J Neurol Neurosurg Psychiatry 93(7):797–798. https://doi.org/10.1136/jnnp-2021-327949
Lim JY, Lim YH, Choi EH (2016) Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: a case report. Medicine (Baltimore) 95(49):e5580. https://doi.org/10.1097/MD.0000000000005580
Martin-Aguilar L, Lleixa C, Pascual-Goni E (2022) Autoimmune nodopathies, an emerging diagnostic category. Curr Opin Neurol 35(5):579–585. https://doi.org/10.1097/WCO.0000000000001107
Van den Bergh PYK, van Doorn PA, Hadden RDM et al (2021) European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. Eur J Neurol 28(11):3556–3583. https://doi.org/10.1111/ene.14959
Liu B, Zhou L, Sun C et al (2023) Clinical profile of autoimmune nodopathy with anti-neurofascin 186 antibody. Ann Clin Transl Neurol 10(6):944–952. https://doi.org/10.1002/acn3.51775
Hadden RD (2009) Deterioration after Guillain-Barré syndrome: recurrence, treatment-related fluctuation or CIDP? J Neurol Neurosurg Psychiatry 80(1):3. https://doi.org/10.1136/jnnp.2008.160069
Dionne A, Nicolle MW, Hahn AF (2010) Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 41(2):202–207. https://doi.org/10.1002/mus.21480
Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS (2015) Bochum ultrasound score versus clinical and electrophysiological parameters in distinguishing acute-onset chronic from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 51(6):846–852. https://doi.org/10.1002/mus.24484
Grimm A, Oertl H, Auffenberg E et al (2019) Differentiation between Guillain-Barré syndrome and acute-onset chronic inflammatory demyelinating polyradiculoneuritis-a prospective follow-up study using ultrasound and neurophysiological measurements. Neurotherapeutics 16(3):838–847. https://doi.org/10.1007/s13311-019-00716-5
Breville G, Lascano AM, Roux-Lombard P, Vuilleumier N, Lalive PH (2021) Interleukin 8, a biomarker to differentiate Guillain-Barre syndrome from CIDP. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000001031
Comi C (2011) Fas-mediated T-cell apoptosis in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 16(Suppl 1):45–47. https://doi.org/10.1111/j.1529-8027.2011.00306.x
Sung JY, Tani J, Park SB, Kiernan MC, Lin CS (2014) Early identification of “acute-onset” chronic inflammatory demyelinating polyneuropathy. Brain 137(Pt 8):2155–2163. https://doi.org/10.1093/brain/awu158
Guemy C, Durand MC, Brisset M, Nicolas G (2023) Changes in electrophysiological findings suggestive of demyelination following Guillain-Barre syndrome: a retrospective study. Muscle Nerve. https://doi.org/10.1002/mus.27803
Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS (2014) Nerve ultrasound score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy. Clin Neurophysiol 125(3):635–641. https://doi.org/10.1016/j.clinph.2013.08.014
Comi C, Osio M, Ferretti M et al (2009) Defective Fas-mediated T-cell apoptosis predicts acute onset CIDP. J Peripher Nerv Syst 14(2):101–106. https://doi.org/10.1111/j.1529-8027.2009.00219.x
Zivkovic SA, Peltier AC, Iacob T, Lacomis D (2011) Chronic inflammatory demyelinating polyneuropathy and ventilatory failure: report of seven new cases and review of the literature. Acta Neurol Scand 124(1):59–63. https://doi.org/10.1111/j.1600-0404.2010.01431.x
Min YG, Hong YH (2020) Treatment-related fluctuations in subacute inflammatory demyelinating polyneuropathy. ENeurologicalSci. https://doi.org/10.1016/j.ensci.2020.100224
Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA (2009) Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 14(4):310–315. https://doi.org/10.1111/j.1529-8027.2009.00243.x
Oh SJ, Lu L, Alsharabati M, Morgan MB, King P (2020) Chronic inflammatory axonal polyneuropathy. J Neurol Neurosurg Psychiatry 91(11):1175–1180. https://doi.org/10.1136/jnnp-2020-323787
Funding
Not applicable.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Ethical approval
Not applicable.
Informed consent
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Inan, B., Bekircan-Kurt, C.E., Demirci, M. et al. Differentiating recurrent Guillain–Barre syndrome and acute-onset chronic inflammatory polyneuropathy: literature review. Acta Neurol Belg (2024). https://doi.org/10.1007/s13760-024-02557-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13760-024-02557-2